Format

Send to

Choose Destination
Interv Cardiol Clin. 2013 Oct;2(4):635-642. doi: 10.1016/j.iccl.2013.05.005. Epub 2013 Jul 11.

Antithrombotic Strategies in Valvular and Structural Heart Disease Interventions: Current Status and Future Directions.

Author information

1
Cardiovascular Department, Ferrarotto Hospital, University of Catania, Via Citelli 6, Catania 95124, Italy; Excellence Through Newest Advances (ETNA) Foundation, Via Citelli 6, Catania 95124, Italy. Electronic address: dcapodanno@gmail.com.
2
Cardiovascular Department, Ferrarotto Hospital, University of Catania, Via Citelli 6, Catania 95124, Italy; Excellence Through Newest Advances (ETNA) Foundation, Via Citelli 6, Catania 95124, Italy.

Abstract

Antithrombotic prophylaxis is the cornerstone of adjunctive pharmacologic therapy in patients undergoing transcatheter intervention for valvular and structural heart disease. However, drugs and doses of antiplatelet and anticoagulant agents are mostly empiric for these indications and typically administered at the operator's discretion. This article describes the rationale for antithrombotic management of patients undergoing transcatheter aortic valve implantation, percutaneous mitral valve repair with the Mitraclip system, patent foramen ovale, and atrial septal defect closure, as well as common strategies for managing antiplatelet and anticoagulant therapy in patients with valvular and structural heart disease undergoing transcatheter procedures.

KEYWORDS:

Bivalirudin; Dual antiplatelet therapy; Heparin; TAVI

PMID:
28582190
DOI:
10.1016/j.iccl.2013.05.005

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center